Harrison Hayes
Harrison Hayes is a life science investment banking boutique dedicated to serving innovation-driven biotechnology, pharmaceutical, and healthcare companies. Since 2007, they have advised clients on over $25 billion worth of deals across various sectors including biotech, pharma, digital health, and medical devices. The firm emphasizes healthcare heritage, results, expert teams, and a client-first approach, supporting a broad range of services such as M&A, licensing deals, royalty monetization, and strategic advisory. They focus on creating tailored strategies for growth, innovation, and market expansion in the healthcare industry.
Industries
Nr. of Employees
small (1-50)
Harrison Hayes
New York, New York, United States, North America
Services
Sell-side investment banking services including preparation, buyer outreach, and transaction execution for life sciences companies.
Buy-side advisory covering target identification, negotiation, modeling and integration analysis to support acquisitions and strategic growth.
End-to-end licensing transaction support from sourcing through negotiation and closing, for both pre-commercial and commercial-stage assets.
Structuring and execution of royalty monetization transactions to unlock non-dilutive capital linked to future product revenues.
Tailored financing outreach and strategic advisory to align capital solutions with client management and shareholder objectives.
Sell-side investment banking services including preparation, buyer outreach, and transaction execution for life sciences companies.
Buy-side advisory covering target identification, negotiation, modeling and integration analysis to support acquisitions and strategic growth.
End-to-end licensing transaction support from sourcing through negotiation and closing, for both pre-commercial and commercial-stage assets.
Structuring and execution of royalty monetization transactions to unlock non-dilutive capital linked to future product revenues.
Tailored financing outreach and strategic advisory to align capital solutions with client management and shareholder objectives.
Expertise Areas
- M&A advisory for life sciences
- Commercial due diligence and market landscaping
- Licensing and deal structuring
- Royalty monetization and alternative financing
Key Technologies
- Next-generation sequencing (NGS)
- Companion diagnostics
- Digital health platforms / health IT
- Remote monitoring and software-enabled medical devices
News & Updates
A report on the growth of the US life sciences sector and related market insights.
The FDA is re-evaluating how drug names influence consumer and healthcare provider perceptions, with a new study involving interviews and analysis of drug name suggestiveness.
A report on the growth of the US life sciences sector and related market insights.
The FDA is re-evaluating how drug names influence consumer and healthcare provider perceptions, with a new study involving interviews and analysis of drug name suggestiveness.